Nakamoto (NAKA) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We may be unable to effectively manage future growth
2. 02We will need additional financing in the future, which may not be available when needed or may be costly and dilutive
3. 03We may incur significant debt to finance our operations
4. 04There may be uncertainty of profitability
5. 05Our business may suffer if we are unable to attract or retain talented personnel
6. 06The lack of available and cost-effective directors and officer’s insurance coverage in our industry may cause us to be unable to attract and retain qualified executives, and this may result in our inability to further develop our business
7. 07Management of growth will be necessary for us to be competitive
8. 08The failure to enforce and maintain our intellectual property rights could adversely affect the value of the Company
9. 09Laws and regulations affecting the medical cannabis industry are constantly changing, which could detrimentally affect our operation
10. 10If we expand into other states, we will have to ensure compliance with all of the regulations of those states, which may be different from the laws in the State of Utah
11. 11If we incur substantial liability from litigation, complaints, or enforcement actions, our financial condition could suffer
12. 12There can be no assurance that our current and future strategic alliances or expansions of scope of existing relationships will have a beneficial impact on our business, financial condition and results of operations
13. 13We may face unfavorable publicity or consumer perception
14. 14We are subject to general economic risks
15. 15Provisions in our governing documents and Utah law may have an anti-takeover effect, and there are substitutional regulatory limitations on changes of control of bank holding companies
16. 16Our brand is integral to our success. If we fail to effectively maintain, promote, and enhance our brand in a cost-effective manner, our business and competitive advantage may be harmed
17. 17The market for our model and services is new, rapidly evolving, and increasingly competitive, as the healthcare industry in the United States is undergoing significant structural change and consolidation, which makes it difficult to forecast demand for our data or services
18. 18Competitive platforms or other technological breakthroughs for the monitoring, management, treatment, or prevention of medical conditions may adversely affect demand for our offerings
19. 19We operate in highly competitive markets and face competition from large, well-established healthcare providers, traditional retailers, pharmaceutical providers, and technology companies with significant resources, and, as a result, we may not be able to compete effectively
20. 20Further expansion efforts would likely significantly increase our operational expenses
21. 21The Company may sustain losses that cannot be recovered through insurance or other preventative measures
22. 22Risks of Government Action and Regulatory Uncertainty
23. 23HIPAA requires covered entities and business associates, such as us, to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information
24. 24In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities and business associates for compliance with the HIPAA privacy and security rules
25. 25We may become subject to the Anti-Kickback Statute, Stark Law, False Claims Act, Civil Monetary Penalties Law and may be subject to analogous provisions of applicable state laws and could face substantial penalties if we fail to comply with such laws
26. 26Civil Monetary Penalties Law
27. 27Litigation or legal proceedings could expose us to significant liabilities and damage our reputation
28. 28Our business and financial performance may be adversely affected by downturns in the target markets that we serve or reduced demand for the types of services we offer
29. 29Changes within the alternative medicine industry or the healthcare industry may adversely affect our financial performance
30. 30Failure in the Company’s information technology systems or delays or failures in the development and implementation of updates or enhancements to those systems could significantly delay billing and otherwise disrupt the Company’s operations or patient relationships
31. 31The risk of malpractice suits is significant in the medical profession. A rise in malpractice suits, or changes in laws related to malpractice, can increase our insurance costs and potentially lead to significant financial payouts
32. 32Changes in the identity, ownership structure and strategic goals of our competitors and the emergence of new competitors in our target markets may harm our financial performance
33. 33We may be unable to respond to the rapid technological change in the industry and such change may increase costs and competition that may adversely affect our business
34. 34Our business and operations would be adversely impacted in the event of a failure or interruption of our information technology infrastructure or as a result of a cybersecurity attack
35. 35Changes in our effective tax rate may impact our results of operations
36. 36Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could significantly affect our financial results

Risks Related to Our Common Stock and Securities

1. 37We may need additional capital that will dilute the ownership interest of investors
2. 38We will be controlled by our existing majority shareholder
3. 39We do not expect to pay any dividends on our common stock
4. 40We are eligible to be treated as an “emerging growth company” as defined in the JOBS Act, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make the Common Shares less attractive to investors
5. 41Costs and expenses of being a reporting company under the 1934 Securities Exchange Act may be burdensome and prevent us from achieving profitability
6. 42Since our shares of Common Stock may be thinly traded it is more susceptible to extreme rises or declines in price, and you may not be able to sell your shares at or above the price paid
7. 43Because we do not expect to pay any dividends on our common stock for the foreseeable future, investors in this offering may never receive a return on their investment
8. 44There could be unidentified risks involved with an investment in our securities
9. 45We may not be able to satisfy the continued listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq
10. 46The market price of our common stock may fluctuate, and you could lose all or part of your investment
11. 47If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares
12. 48INFORMATION REGARDING FORWARD-LOOKING STATEMENTS